Additionally, a reduction in cisplatin’s cytotoxicity, accumulation, survival, and increased resistance has occurred in colorectal, head, and neck cancers when OCT3 activity was suppressed, and in lung cancer when OCT6 expression was restricted. This evidence concerns the gene SLC22A16 and head and neck cancer.